Assessment of the effectiveness of a home-based care program for patients coinfected with tuberculosis and human immunodeficiency virus after discharge from a reference hospital in South-Eastern Brazil  by Plá Bento, Carlos Alessandro & Pietra Pedroso, Enio Roberto
O
R
IG
IN
A
L 
 
A
R
TI
CL
E
594
Assessment of the effectiveness of a home-based care 
program for patients coinfected with tuberculosis and 
human immunodeficiency virus after discharge from a 
reference hospital in South-Eastern Brazil
Authors
Carlos Alessandro Plá 
Bento1
Enio Roberto Pietra 
Pedroso2
1Master’s Degree in 
Tropical Medicine at Health 
Science’s(Infectology 
and Tropical Medicine) 
Postgraduate Course by 
the Medicine School of 
Universidade Federal de 
Minas Gerais. 
Hospital Eduardo de 
Menezes (HEM) - 
Fundação Hospitalar do 
Estado de Minas Gerais 
(FHEMIG), Belo-
Horizonte, MG, Brazil. 
2Full Professor at 
Departamento de Clínica 
Médica of the Medicine 
School of Universidade 
Federal de Minas Gerais - 
Centro de Pós-Graduação 
em Medicina Tropical da 
Faculdade de Medicina da 
Universidade Federal de 
Minas Gerais (FM-UFMG), 
Belo-Horizonte, MG, Brazil 
Submitted on: 03/03/2010
Approved on: 06/29/2010
Correspondence to: 
Carlos Alessandro Plá 
Bento 
Hospital Eduardo 
de Menezes, Rua Dr. 
Cristiano Resende, 2213 – 
Bonsucesso, 30622-020, 
Belo Horizonte, MG, 
Brazil.
Fax: 55 31 3328 5029
E-mail: 
plabento@uol.com.br 
We declare no conﬂ ict of 
interest.
ABSTRACT
The effectiveness of tuberculosis treatment delivered by a home-based care program to patients 
coinfected with HIV was compared with that of a service provided by outpatient departments. A 
retrospective study was made of a cohort of coinfected patients discharged from hospital between 
January 1998 and December 2002 who had been followed-up for one year within one of these pro-
grams. Two-hundred-and-forty-three patients who met the inclusion criteria were grouped accord-
ing to their treatment program (group 1 received home-based care; group 2 attended outpatient 
departments) and then paired one-to-one across the groups by gender, age and level of education. 
Only 48 patients from each group could be paired. Apart from the duration of HIV infection, there 
were no statistically signifi cant differences (P < 0.05) between patients in the two groups with respect 
to social-demographic status and clinical or laboratory characteristics. In group 1, 75.0% of patients 
attained successful tuberculosis treatment compared with 72.9% of those in group 2 (P = 0.816). Treat-
ment was abandoned by 22.9% of patients in group 1 and by 54.2% of those in group 2 (P = 0.008). 
The death rate within one year after discharge was 20.8% for group 1 compared with 6.3% for group 2 
(P = 0.334). Although both programs achieved a similar success rate in the treatment of tuberculosis, 
patients receiving outpatient care were three to eight-times more likely to abandon the program. The 
importance of assigning patients at-risk of abandoning treatment to a home-based care program 
after discharge from hospital is emphasized.
Keywords: AIDS; tuberculosis; treatment outcome; adherence to treatment; home-based care.
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INTRODUCTION
Tuberculosis (TB) is one of the most impor-
tant complications of HIV infection1 and re-
quires multi-drug therapy over an extended 
period. Consequently, for both infections, 
close adherence to the treatment regime 
and careful monitoring of drug resistance 
are critical program issues.2 The successful 
treatment of TB requires appropriate medi-
cation as well as continuous supervision by 
medical staff including the direct observa-
tion of drug intake and monitoring of the 
disease throughout the treatment by bac-
teriological examination of the sputum. If 
all of these criteria are met, the control of 
TB is one of the most cost-effective health 
interventions.3 However, the number of 
TB cases is increasing worldwide, and the 
HIV pandemic is considered to be one of 
its major causes.4,5 In developed countries 
an increase in cases was due to coinfection 
with HIV, and paradoxically, the increase in 
longevity with the emergence of TB in the 
elderly. These groups have accumulated and 
caused cohabiting institutional outbreaks. 
Poorer countries, on the other end, kept and 
maintained high incidence rates increased 
in most of them between past and present 
decades.6 Among the intermediate coun-
tries, some have experienced a gradual re-
duction in the incidence of TB, as is the case 
of Brazil.7,8 TB is known to accelerate the 
progression of HIV and is associated with 
decreased survival.9 Moreover, TB and HIV 
have a number of characteristics in com-
mon and there is a clear requirement for 
an evidence-based international strategy to 
combat both diseases.10 
In Brazil, at least 100,000 individuals are 
coinfected with TB/HIV. Whilst the intro-
Este é um artigo Open Access sob a licença de CC BY-NC-ND
595Braz J Infect Dis 2010; 14(6):594-600
duction of highly active antiretroviral therapy (HAART) 
has resulted in a significant therapeutic breakthrough 
in the treatment of HIV-patients, non-adherence to the 
prescribed regime remains a formidable barrier to
the success of the treatment,11,12 and innovative approach-
es are required in order to increase access and adherence 
to HAART, particularly amongst problematic sectors of 
the community.12-14 Since 1995, the Ministry of Health in 
Brazil has guaranteed the availability of HAART for all 
citizens suffering from AIDS by the establishment of a 
comprehensive national program referred to as the Pro-
grama de Alternativas Assistenciais.15 This program en-
compasses both specialized assistance service (Serviços 
de Atendimento Especializado; SAE) that is delivered by 
outpatient departments of hospitals, and home therapy 
assistance (Assistência Domiciliar Terapêutica; ADT), the 
home-based care service of which is provided by interdis-
ciplinary teams. 
Clearly, the access of HIV-patients to HAART is es-
sential in order to reduce the incidence of HIV-related 
TB.16 However, very few reports have compared the ef-
fectiveness of the intervention provided by the ADT 
program with that of self-administered treatment su-
pervised by SAE in the follow-up of coinfected TB/HIV
patients, especially those recently discharged from 
hospital.9,17 In order to compare the two programs, the 
success rate of TB treatment and the adherence to tu-
berculostatic and antiretroviral therapies of patients 
diagnosed with TB/HIV were monitored over a period 
of one year following their discharge from a hospital in 
Belo Horizonte (MG, Brazil) specializing in infectious 
and parasitic diseases. 
METHODS
Study design
Details of the study were presented and approved by the 
Ethical Committee of UFMG and Hospital Eduardo de 
Menezes. A retrospective study of a cohort of HIV-diag-
nosed patients18 that were treated for TB in the Hospi-
tal Eduardo de Menezes – Fundação Hospitalar do Esta-
do de Minas Gerais (HEM-FHEMIG) during the period 
from January 1st, 1998 to December 31st, 2002 was con-
ducted using the hospital records as reference materials. 
Patients were followed up for one year after their dis-
charge from hospital except when a subject abandoned 
the program or died during the period.
Study population
HIV-diagnosed patients were classified into two groups: 
group 1 consisted of patients who were followed up by 
the ADT program organized by HEM-FHEMIG imme-
diately after their discharge, whilst group 2 included 
patients who were followed up by the SAE program or-
ganized either by HEM-FHEMIG or by the Centro de 
Referência e Treinamento em Doenças Infecciosas e Para-
sitárias Orestes Diniz (Prefeitura Municipal de Belo Hori-
zonte and Hospital das Clínicas da Universidade Federal 
de Minas Gerais). Within each group, all patients older 
than 18 years, of both gender, and living in the metro-
politan area of Belo Horizonte were initially included 
in the study. Patients who had left the hospital against 
medical advice, patients who had not engaged in one of 
the two care programs indicated above, patients who 
had returned to the hospital within seven days of their 
formal discharge, patients who had been transferred to 
other medical centers, and patients who had disappeared 
were excluded from the study. 
A total of 240 patients were initially included in the 
study. The 57 patients comprising group 1 had been fol-
lowed up by ADT for a variable length of time, accord-
ing to the protocol adopted by the team, and were even-
tually transferred to one of the SAE programs. Patients 
received weekly home visits of up to three members of 
an interdisciplinary team composed of physicians, nurs-
es and aides, physical therapist, psychologist and social 
assistant. They earned their medications according to 
demand and control of use was done by counting the 
tablets allowing immediate assessment of adherence to 
therapy. A caregiver was selected and trained to give the 
medications and perform the care directed by the team.
The 183 patients forming group 2 had been followed 
up exclusively by one or both of the SAE programs. Pa-
tients in this group collected their medicines at one-to 
three-monthly intervals from an outpatient department 
and were examined by a consultant infectious diseases 
specialist at that time. The type of assistance delivered to 
the patients after their discharge had been defined accord-
ing to appropriate medical criteria during their period of 
hospital confinement. On this occasion, each patient had 
been accompanied by a relative or a community member 
who had accepted the responsibility of looking after them 
and making sure that the medications were taken as rec-
ommended by the medical team.
Selection of patients
After all of the data pertaining to the patients in the study 
population had been recorded, patients in group 1 were 
paired with those in group 2 on a one-to-one basis with 
respect to gender, age (± 5 years) and educational level 
(illiterate, primary school, secondary school or university 
degree). All three features should be fulfilled. Patients in 
group 1 who did not find perfect matches in group 2 were 
excluded. 
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Determination of treatment outcome
At the conclusion of the follow-up period, patients were 
classified as having (I) adhered to the treatment, (II) aban-
doned the treatment, or (III) died (regardless of the cause 
of death). Patients were deemed to have adhered to the 
treatment if they continued their TB medication for more 
than 80% of the time previously specified and failed with 
the antiretroviral treatment for less than 30 days. Patients 
who had adhered to the treatment were deemed to have 
received a successful TB treatment if they completed the 
treatment regimen and achieved clinical recovery,19 or if 
they attained a cure of the disease (that is, two consecu-
tive negative bacilloscopy tests and presenting clinical 
recovery). 
Statistical analysis
All data were recorded using appropriate standard-
ized forms. Statistical analyses were carried out using 
SPSS (SSPS Inc., Chicago, IL) version 11.0 software. 
Descriptive and univariate analyses employing the χ2 
test and Fischer’s exact test were used to detect statisti-
cally significant differences between categories. Contin-
uous variables were tested by comparison of their mean 
values within a 95% confidence interval. In order to 
perform multiple regression univariate analysis, all vari-
ables presenting P < 0.25 were considered: differences 
were deemed significant at P < 0.05. 
RESULTS 
Of the total 240 patients, 57 were included in group 1 
and 183 patients in group 2. Adherence to treatment one 
year after hospital discharge was achieved in 50.9% of 
patients in group 1 and 53% of those in group 2. The 
abandonment of treatment one year after hospital dis-
charge was developed by 28.1% of patients in group 1 
and 42.1% of patients in group 2 with p = 0.129 with a 
relative risk (RR) of 0.65 confidence interval (CI) 95% 
from 0.37 to 1.13. The death occurred in 21% of patients 
in group 1 and 4.9% of patients in group 2. The comple-
tion of TB treatment was achieved by 73.7% of patients 
in group 1 versus 72.7% in group 2 with p = 0.882 95% 
CI from -0.14 to 0.12.20
Only 48 patients from group 1, originally comprising 
57 individuals, could be paired with patients of group 2, 
thus the total number of patients included in the study 
was 96. Other than the duration of HIV infection, there 
were no statistically significant differences between pa-
tients in groups 1 and 2 with respect to their social-demo-
graphic status or their clinical or laboratory characteris-
tics at discharge from the hospital.
The average age of all patients was 34.8 years, 62.5% 
were males, 89.6% had attended school for 8 years 
maximum and 65.6% lived in the city of Belo Hori-
zonte. Most of the patients were single (63.5%) and 
in 47.9% of the cases HIV infection had resulted from 
sexual intercourse with men. The average duration of in-
fection for patients of group 1 was 27.8 months (stand-
ard deviation {SD} = 39.1 months), whilst in group 
2 the average was 18.1 months (SD = 33.7 months), val-
ues that were signifi cantly different at P < 0.001 (Table 1). 
The average time of hospital confi nement was 58.1 days for 
patients of group 1 and 48.2 days for those of group 2.
Prior to the start of the therapeutic program, 40 pa-
tients (83.3%) of group 1 presented an average T CD4+ 
lymphocyte count of 182.6 cells/mm3 (SD = 49.0), and 
39 patients (81.3%) of group 2 exhibited an average T 
CD4+ lymphocyte count of 151.0 cells/mm3 (SD = 37.6). 
When the results were dichotomized with respect to the 
T CD4 lymphocyte count level of 200 cells/mm3, 68.3% 
of group 1 and 45.5% of group 2 have shown values be-
low this level, a difference between groups that was not 
significant (P = 0.678). The mean value of log10(viral 
load) for patients in group 1 was 4.01 (equivalent to 
10233 copies/mm3 of viral RNA; SD = 1.52), whilst 
in group 2 the mean value was 4.52 (equivalent to 
33,113 copies/mm3 of viral RNA; SD = 1.34). When the 
results were dichotomized with respect to the median 
baseline HIV level for log10(viral load) of 2.6 (equivalent 
to 400 copies/mm3 of viral RNA), 26.5% of group 1 and 
12.1% of group 2 presented values below this level, a differ-
ence between groups that was not signifi cant (P = 0.122).
The average incidence of opportunistic infection pri-
or to entry into one of the scheduled therapy programs 
was 3.5 for group 1 and 3.0 for group 2. Mycobacterio-
sis was diagnosed definitely in 34.4% of the patients, and 
for the majority (63.6%), the presence of Mycobacterium 
tuberculosis was confirmed. The lungs were the organs 
most frequently affected by the disease (47.9%). The 
therapy regimens employed rifampicin, isoniazid and 
pirazinamide (scheme S1; 57.3%), or S1 reinforced with 
etambutol (scheme R-S1; 25%), or one of the regimens 
containing streptomycin (17.7%).
Table 2 presents a comparison between groups 1 and 
2 with respect to the treatment outcome for patients after 
one year of being discharged from hospital. In group 1,
56.3% of the patients adhered to the treatment, whilst in 
group 2 only 39.6% adhered to the treatment (P = 0.102).
Moreover, 22.9% of group 1 patients abandoned the treat-
ment during the year, whilst the percentage was much 
higher (54.2%) in group 2 with P = 0.008 and relative risk 
(RR) = 3.36. The number of deaths during the follow-up 
period was 20.8% in group 1 but only 6.3% in group 2 
(P = 0.334). The treatment for tuberculosis was success-
ful in 75% of the patients of group 1 and in 72.9% of 
group 2 (P = 0.816).
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Table 1. Statistical comparison of the parameters, determined prior to discharge from hospital, of TB patients 
coinfected with HIV who were to be supported by either an ADT (group 1) or an SAE (group 2) program
Initial parameters P valuea
Treatment schedule for TB prescribed for 6 months 0.669
Treatment schedule for TB prescribed for 9 months 0.668
Treatment schedule for TB prescribed for 12 months 0.374
Site of TB infection: lungs 0.414
Site of TB infection: miliary 0.665
Site of TB infection: disseminated 0.460
Site of TB infection: pleural 0.064
Site of TB infection: lymph nodal 0.653
Site of TB infection: central nervous system  0.117b
Site of TB infection: osteoarticular 0.315
Site of TB infection: urinary tract 0.315
Site of TB infection: others 0.504
Source of infection: sexual intercourse with men  0.290
Source of infection: sexual intercourse with women  0.996
Source of infection: intravenous drug users  0.916
Source of infection: receivers of blood products 0.367
TB therapy employed: S1c 0.149
TB therapy employed: R-S1d 0.157
TB therapy employed: scheme including streptomycin 0.789
Definite diagnosis for Mycobacteriosis  0.566
Definite diagnosis for Mycobacterium tuberculosis 0.553b
Period of HIV infection  < 0.001
T CD4+ lymphocyte count < 200 cells/mm3 0.678
Viral load < 2.60 log10 (equivalent to 400 copies of viral RNA) 0.122
aDetermined using the χ2 test unless otherwise indicated.
bDetermined using Fisher’s exact test.
cTreatment scheme S1: rifampicin, isoniazid and pirazinamide. 
dAs treatment scheme S1 but reinforced with etambutol.
Table 2. Statistical comparison of treatment outcome parameters, determined one year after discharge 
from hospital, of TB patients coinfected with HIV supported by either an ADT (group 1) or an SAE (group 2) 
program
Treatment outcome parameters  P valuea
Successful treatment of TB 0.816
Death after discharge from the hospital 0.334
Abandonment of treatment in the period 30 days up to 
1 year after discharge from hospital  0.008 (RR: 3.36)
Adherence to treatment up to one year after discharge from hospital  0.102
Final T CD4+ lymphocyte count < 200 cells/mm3 0.112
Final viral load < 2.60 log10 (equivalent to 400 copies of viral RNA) 0.019 (RR: 4.25)
aDetermined using the χ2 test; RR, relative risk.
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Logistic regression analysis of the data (Table 3) indi-
cated a signifi cant association, within a 95% confi dence in-
terval, between abandonment of treatment and the program 
scheduled for group 2 (P = 0.042; RR = 8.09). The differ-
ence between the initial and the fi nal mean values of the 
T CD4+ lymphocyte count for group 1 was 160.5 cells/mm3 
(SD = 49.0) and for group 2 was 74.1 cells/mm3 (SD = 37.6). 
When the results from the two groups were dichotomised 
with respect to 200 cells/mm3, a P value of 0.112 was ob-
tained according to the χ2 test, indicating that the difference 
between the groups was not signifi cant. The mean log10(viral 
load) value determined one year after discharge from the 
hospital was reduced to 1.46 (equivalent to 29 copies of viral 
RNA) for group 1 patients compared with 0.73 (equivalent to 
fi ve copies of viral RNA) for those in group 2, values that 
were not signifi cantly different within the 95% confi dence in-
terval. However, when dichotomised with respect to the level 
of log10(viral load) of 2.6 (equivalent to 400 copies of viral 
RNA) there was a signifi cant correlation with the treatment 
program (P = 0.019) such that group 1 patients presented a 
4.25-fold greater likelihood of attaining a viral load of less 
than 400 copies/mm3 of viral RNA compared with patients 
in group 2. 
DISCUSSION
The only signifi cant differences that could be detected, prior 
to their discharge from hospital, between patients in the two 
groups was that those in group 1 had been infected with 
HIV for a longer period than those in group 2. This is in line 
with the tendency to treat those patients with more complex 
disorders in their own homes since, if HIV-therapy is not 
effectively delivered, the progression of the infection results 
in an increase in morbidity.21 
There was no signifi cant difference between the success 
rates of the TB therapy for patients treated under the ADT 
or the SAE program, and treatment outcome was similar 
to that established in an analogous survey conducted in 
São Paulo in which 74% of HIV coinfected patients attained 
a cure and 18% abandoned the therapy during the prescribed 
period.22 The TB cure rate achieved by this study were higher 
than the rates obtained by other national surveys with pa-
tients coinfected with HIV who achieved TB cure rates be-
low 58.8%.23-25 However, the success rates recorded for both 
groups of patients in the present study were lower than 
those observed in previous studies26-32 of populations, con-
taining varying percentages of HIV-infected patients, that 
had been treated under a directly observed therapy (DOT) 
Table 3. Multivariate analysis of TB patients coinfected with HIV who were supported by either an ADT 
(group 1) or an SAE (group 2) program and who had abandoned therapy during a one year period after 
discharge from hospital
Program  Variablesa P valueb
ADT Treatment schedule for TB prescribed for 12 months 0.847
 Source of infection: use of intravenous drugs 0.063
 TB therapy employed: S1c 0.616
 TB therapy employed: scheme including streptomycin 0.877
 Definite diagnosis for Mycobacteriosis 0.143
 Site of TB infection: lungs 0.740
 Number of previous hospital confinements  0.835
SAE Treatment schedule for TB prescribed for 12 months 0.045 (RR: 8.09)
 Source of infection: sexual intercourse with women 0.798
 Definite diagnosis for Mycobacteriosis 0.108
 Number of previous hospital confinements 0.086
 Duration of previous hospital confinements 0.220
 Gender  0.540
 Age 0.574
aOnly variables presenting P < 0.25 were considered in the analysis.
bRR, relative risk.
cTreatment scheme S1: rifampicin, isoniazid and pirazinamide.
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program. Furthermore, the number of patients who attained 
a cure under either treatment program in the present sur-
vey did not reach the 85% standard set by the World Health 
Organization.10,33
Various studies have indicated that the success rate of TB 
therapy in patients coinfected with HIV is low not only be-
cause of a higher rate of morbidity amongst such patients, but 
also because the access to such groups is more diffi cult.17,27,34 
Furthermore, there is copious evidence to suggest that TB can 
accelerate the progression of HIV infection and thus reduce 
the chances of survival.3,35 In the present study, the rate of 
morbidity was higher amongst patients included in group 1 
(20.8%) compared to group 2 (6.3%), although the differ-
ence was not statistically signifi cant (P = 0.816). Interfering 
factors, such as the distribution of patients between the ADT 
and SAE programs, may have contributed to this result de-
spite the similarity of the other parameters between the two 
groups. Since the study was of a retrospective nature, none of 
the parameters measured were under strict control. 
Patients in the SAE program were, typically, three-times 
more likely to abandon their treatment than those in the ADT 
program. Moreover, amongst patients whose TB therapy was 
prolonged (i.e. ca. 12 months), those in group 2 were eight-
times more likely to abandon the treatment compared with 
their counterparts in group 1. 
Within TB treatment, the necessary levels of adherence 
are signifi cantly different from those demanded for adequate 
HIV-treatment, mainly because of the need to control the se-
lection pressure of HIV-resistant strains.36 It is thus accepted 
that TB patients need to take at least 80% of the prescribed 
tuberculostatic drugs in order to attain a complete cure,19,34,36 
whilst HIV-patients need to take at least 95% of the antiret-
rovirals prescribed for an indefi nite period.11,12,37,38 Since the 
proportion of patients presenting a fi nal load of less than 400 
copies/mm3 of viral RNA was statistically superior in group 
1, it is clear that adherence to the antiretroviral treatment was 
observed by most of the patients included in the ADT pro-
gram. Therefore, it is suggested that short term TB treatments 
(of 6 to 9 months) for patients coinfected with HIV can be 
followed-up by either ADT or SAE programs with compara-
ble results. However, for TB treatments requiring longer peri-
ods of medication (ca. 12 months) and almost total adherence 
to the regime, the follow-up of HIV coinfected patients would 
be more appropriate if provided under a ADT program. 
The TB treatment delivered by both ADT and SAE pro-
grams offered to HIV-patients needs to be improved in order 
for the success rate to be raised to the levels recommended 
by the World Health Organization.10 New strategies must be 
designed in order to reach the more problematic sectors of 
the community including, for example, the adoption of spe-
cial techniques for drug addicts and much closer collabora-
tion with community health carers. Such work must be un-
dertaken in an integrated manner by interdisciplinary teams 
of home-carers and those from outpatient departments.39 
TB patients, coinfected with HIV, for whom a long duration 
therapy is prescribed should preferably be assisted by an ADT 
program. In further considerations of ADT programs, other 
parameters that inﬂ uence adherence to treatment must be 
considered, the treatment success rate and adherence must 
be constantly checked and compared with SAE and DOT 
programs,37 and the follow-up period of patients must be 
longer than one year in order to allow for the evaluation of 
possible fatigue to antiretroviral adherence.40 
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